Suppr超能文献

包埋包含体于可溶解微针眼部贴剂系统中提高氟康唑治疗真菌性角膜炎的疗效

Incorporation of Inclusion Complexes in the Dissolvable Microneedle Ocular Patch System for the Efficiency of Fluconazole in the Therapy of Fungal Keratitis.

机构信息

Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia.

Faculty of Mathematics and Natural Sciences, Bogor Agricultural University, Bogor 16680, Indonesia.

出版信息

ACS Appl Mater Interfaces. 2024 May 22;16(20):25637-25651. doi: 10.1021/acsami.3c19482. Epub 2024 May 10.

Abstract

Fluconazole (FNL) is one of the first-line treatments for fungal keratitis as it is an effective broad-spectrum antimicrobial commonly administered orally or topically. However, FNL has a very low water solubility, limiting its drug formulation, therapeutic application, and bioavailability through tissues. To overcome these limitations, this study aimed to develop FNL inclusion complexes (FNL-IC) with cyclodextrin (α-cyclodextrin, sulfobutylether-β-cyclodextrin, and hydroxypropyl-γ cyclodextrin) and incorporate it into a dissolvable microneedle (DMN) system to improve solubility and drug penetration. FNL-IC was evaluated for saturation solubility, Fourier transform infrared spectroscopy, differential scanning calorimetry, in vitro release, minimum inhibitory concentration, minimum fungicidal concentration, and time-killing assay. DMN-FNL-IC was evaluated for mechanical and insertion properties, surface pH, moisture absorption ability, water vapor transmission, and drug content recovery. Moreover, ocular kinetic, ex vivo antimicrobial, in vivo antifungal, and chorioallantoic membrane (HET-CAM) assays were conducted to assess the overall performance of the formulation. Mechanical strength and insertion properties revealed that DMN-FNL-IC has great mechanical and insertion properties. The in vitro release of FNL-IC was significantly improved, exhibiting a 9-fold increase compared to pure FNL. The ex vivo antifungal activity showed significant inhibition of from 6.54 to 0.73 log cfu/mL or 100-0.94%. In vivo numbers of colonies of 0.87 ± 0.13 log cfu/mL (F2), 4.76 ± 0.26 log cfu/mL (FNL eye drops), 3.89 ± 0.24 log cfu/mL (FNL ointments), and 8.04 ± 0.58 log cfu/mL (control) showed the effectiveness of DMN preparations against other standard commercial preparations. The HET-CAM assay showed that DMN-FNL-IC (F2) did not show any vascular damage. Finally, a combination of FNL-IC and DMN was developed appropriately for ocular delivery of FNL, which was safe and increased the effectiveness of treatments for fungal keratitis.

摘要

氟康唑(FNL)是治疗真菌性角膜炎的一线药物之一,因为它是一种有效的广谱抗菌药物,通常口服或局部使用。然而,FNL 的水溶性非常低,限制了其药物制剂、治疗应用和通过组织的生物利用度。为了克服这些限制,本研究旨在用环糊精(α-环糊精、磺丁基醚-β-环糊精和羟丙基-γ-环糊精)制备 FNL 包合物(FNL-IC),并将其纳入可溶解的微针(DMN)系统中,以提高溶解度和药物渗透。评估了 FNL-IC 的饱和溶解度、傅里叶变换红外光谱、差示扫描量热法、体外释放、最小抑菌浓度、最小杀菌浓度和时间杀伤试验。评估了 DMN-FNL-IC 的机械和插入特性、表面 pH 值、吸湿性、水蒸气透过率和药物含量回收率。此外,还进行了眼部动力学、离体抗菌、体内抗真菌和鸡胚尿囊膜(HET-CAM)试验,以评估制剂的整体性能。机械强度和插入特性表明,DMN-FNL-IC 具有良好的机械和插入特性。FNL-IC 的体外释放得到了显著改善,与纯 FNL 相比,释放提高了 9 倍。离体抗真菌活性显示出显著的抑制作用,从 6.54 对数减少到 0.73 对数 cfu/mL 或 100-0.94%。体内菌落数为 0.87±0.13 对数 cfu/mL(F2)、4.76±0.26 对数 cfu/mL(FNL 滴眼液)、3.89±0.24 对数 cfu/mL(FNL 软膏)和 8.04±0.58 对数 cfu/mL(对照组),表明 DMN 制剂对其他标准商业制剂具有有效性。HET-CAM 试验表明,DMN-FNL-IC(F2)未显示任何血管损伤。最后,适当地将 FNL-IC 和 DMN 组合用于 FNL 的眼部递药,既安全又提高了真菌性角膜炎治疗的效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验